Melanocortin Receptor Class Effect: Nausea as a Shared Side Effect Across Multiple Peptides
Nausea is identified as a class-wide side effect of melanocortin receptor agonist peptides, not unique to PT-141 alone. PT-141, Melanotan II, and setmelanotide all share this side effect profile due to their shared mechanism of MC4R activation adjacent to the brain's vomiting center. Understanding this class effect has implications for anticipating and managing side effects across all melanocortin-targeting peptides.
Melanotan II Shares Nausea Side Effect Profile with PT-141
PT-141 is derived from Melanotan II, and both peptides share the nausea side effect due to their shared melanocortin receptor class activity. This indicates the nausea is a class effect of melanocortin agonists rather than unique to PT-141 specifically. No dosage information is provided for either peptide.